ArticleCancers2025
Assessing Oncologic and Functional Outcomes of 3D Image-Guided Robotic-Assisted Partial Nephrectomy (3D-IGRAPN): A Prospective Study (UroCCR-186).
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03293563 (UroCCR Database), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)
Who cites it
2 citing papers in PubMed.
- Robot-assisted versus open surgery for multiple ipsilateral renal tumors: a multicenter matched cohort study (UroCCR-60).Journal of robotic surgery · 2026Article
- Renal Functional Outcomes in Robot-Assisted Partial Nephrectomy with Minimum Layer Resection Using Virtual Three-Dimensional Image Assistance.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND/
objectivesThree-dimensional (3D) image-guided robotic-assisted partial nephrectomy (3D-IGRAPN) integrates patient-specific anatomical models to optimize surgical planning and intraoperative guidance in the management of renal tumors. This study aimed to assess medium-term functional and oncologic outcomes of 3D-IGRAPN in a large, prospective cohort.
methodsAll consecutive patients undergoing 3D-IGRAPN between January 2016 and March 2023 at a tertiary referral center were prospectively included in the UroCCR database (NCT03293563). Patient-specific 3D models were generated from preoperative CT scans and used intraoperatively. The primary endpoint was trifecta achievement, defined as an absence of major complications (Clavien-Dindo ≥ 3), negative surgical margins for malignant tumors, and ≥90% preservation of baseline renal function at 3 months. Secondary endpoints included functional outcomes, complication rates, local recurrence, and metastasis rates, as well as cancer-specific and overall survivals.
resultsAmong 568 patients (586 surgeries), the trifecta was achieved in 55.2% of evaluable malignant cases. Severe complications occurred in 33 cases (5.6%), and positive surgical margins were reported in 27 cases (5.1%) out of 528 surgeries involving malignant lesions. Renal function was preserved in 59.9% of patients at 3 months. At a mean follow-up of 31.5 months, recurrence and metastasis rates were 7.4% and 8.6%, respectively. Cancer-specific and overall survival at follow-up were 96.5% and 89%.
conclusions3D-IGRAPN demonstrates favorable functional and oncologic outcomes, even in complex tumors. These results support the integration of 3D modeling as a standard tool in image-guided nephron-sparing surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.